Michael Huang
19Patents
5h-index
19Co-inventors
59Inventor score
Filing activity: Mar 7, 2005 → Apr 26, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10849908B2 | Corticotropin releasing factor receptor antagonists | Chemistry; Metallurgy | 13 | Active |
| US11007201B2 | Corticotropin releasing factor receptor antagonists | Chemistry; Metallurgy | 11 | Active |
| US7348034B2 | Plant based formulations for improving skin moisture, texture, and appearance | Human Necessities | 5 | Expired |
| US11344557B2 | Corticotropin releasing factor receptor antagonists | Chemistry; Metallurgy | 5 | Active |
| US11351177B2 | Corticotropin releasing factor receptor antagonists | Chemistry; Metallurgy | 5 | Active |
| US11311549B2 | Corticotropin releasing factor receptor antagonists | Chemistry; Metallurgy | 5 | Active |
| US10959996B2 | Methods for the treatment of abnormal involuntary movement disorders | Human Necessities | 5 | Active |
| US11419822B2 | High concentration formulations of anti-CSF1 and anti-CSF1R antibodies | Chemistry; Metallurgy | 1 | Active |
| US7419689B2 | Plant-based formulations for improving liver health | Human Necessities | 1 | Expired |
| US7718201B2 | Method of inducing liver phase II enzymes | Human Necessities | 0 | Active |
| US11446291B2 | Methods for the treatment of abnormal involuntary movement disorders | Human Necessities | 0 | Active |
| US11357772B2 | Methods for the treatment of abnormal involuntary movement disorders | Human Necessities | 0 | Active |
| US12115166B2 | Corticotropin releasing factor receptor antagonists | Chemistry; Metallurgy | 0 | Active |
| US12178915B2 | High concentration formulations of anti-CSF1 and anti-CSF1R antibodies | Chemistry; Metallurgy | 0 | Active |
| US11648244B2 | Methods for the treatment of abnormal involuntary movement disorders | Human Necessities | 0 | Active |
| US11564917B2 | Methods for the treatment of abnormal involuntary movement disorders | Human Necessities | 0 | Active |
| US12016858B2 | Methods for the treatment of abnormal involuntary movement disorders | Human Necessities | 0 | Active |
| US11752096B2 | Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors | Chemistry; Metallurgy | 0 | Active |
| US12005065B2 | Corticotropin releasing factor receptor antagonists | General | 0 | Revoked |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.